/TARA
TARA Stock - Protara Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$4.96-5.25%
$0.28 (-5.25%) • Jan 13
73
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.60
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.63
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+141.7%upside
Target: $12.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TARA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.92 – $5.01
TARGET (TP)$12.00
STOP LOSS$4.57
RISK/REWARD1:17.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.42
52W High$7.82
52W Low$2.77
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-341,000 | N/A | N/A | $-196,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-49,154,000 | $-43,613,000 | $-67,062,000 | $-47,489,000 | $-34,444,000 |
| Net Income | $-44,596,000 | $-40,420,000 | $-65,952,000 | $-47,252,000 | $-33,978,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.17 | $-3.57 | $-5.86 | $-4.20 | $-4.70 |
Company Overview
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$19
Average Target
↑ 289.4% Upside
Now
$12
Low
$19
Average
$24
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 7th 2026 | Piper Sandler | Initiation | Overweight | $24 |
| April 16th 2025 | Scotiabank | Initiation | Sector Outperform | $12 |
| March 14th 2025 | Cantor Fitzgerald | Initiation | Overweight | - |
| July 10th 2023 | Guggenheim | Resumed | Buy | $22 |
Earnings History & Surprises
TARABeat Rate
78%
Last 18 quarters
Avg Surprise
+14.6%
EPS vs Estimate
Beats / Misses
14/2
2 met exactly
Latest EPS
$-0.31
Q4 2025
EPS Surprise History
Q1 24
+12.6%
$-0.90vs$-1.03
Q2 24
+2.0%
$-0.97vs$-0.99
Q3 24
+45.1%
$-0.45vs$-0.82
Q4 24
0.0%
$-0.50vs$-0.50
Q1 25
+15.8%
$-0.48vs$-0.57
Q2 25
+38.3%
$-0.29vs$-0.47
Q3 25
+18.6%
$-0.35vs$-0.43
Q4 25
+20.5%
$-0.31vs$-0.39
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 4, 2026 | $-0.36 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.39 | $-0.31 | +20.5% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-0.43 | $-0.35 | +18.6% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.47 | $-0.29 | +38.3% | ✓ BEAT |
Q1 2025 | Mar 5, 2025 | $-0.57 | $-0.48 | +15.8% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.50 | $-0.50 | 0.0% | = MET |
Q3 2024 | Aug 6, 2024 | $-0.82 | $-0.45 | +45.1% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.99 | $-0.97 | +2.0% | ✓ BEAT |
Q1 2024 | Mar 13, 2024 | $-1.03 | $-0.90 | +12.6% | ✓ BEAT |
Q4 2023 | Nov 3, 2023 | $-1.10 | $-0.87 | +20.9% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.97 | $-1.00 | -3.1% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-1.00 | $-0.80 | +20.0% | ✓ BEAT |
Q1 2023 | Mar 8, 2023 | $-0.77 | $-0.84 | -9.1% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.85 | $-0.68 | +20.0% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-1.13 | $-0.80 | +29.2% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-1.09 | $-0.96 | +11.9% | ✓ BEAT |
Q1 2022 | Mar 9, 2022 | $-0.94 | $-0.91 | +3.2% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-1.15 | $-0.96 | +16.5% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-1.14 | $-1.14 | 0.0% | = MET |
Latest News
Protara Therapeutics Enters 2026 With Advancing TARA-002 Programs, Registrational Trials And Extended Cash Runway Into 2028
📈 PositiveBenzinga•Jan 12, 2026, 12:17 PM
Protara Therapeutics shares are trading higher after the company announced dosing of first patient in Phase 3 registrational THRIVE-3 clinical trial of IV Choline Chloride. Piper Sandler initiated coverage on the stock with an Overweight rating and announced a $24 price target.
📈 PositiveBenzinga•Jan 7, 2026, 05:57 PM
Piper Sandler Initiates Coverage On Protara Therapeutics with Overweight Rating, Announces Price Target of $24
📈 PositiveBenzinga•Jan 7, 2026, 01:10 PM
Protara Therapeutics Announces Patient Dosing In Phase 3 Registrational THRIVE-3 Clinical Trial Evaluating IV Choline Chloride In Patients Receiving Long-Term Parenteral Support
📈 PositiveBenzinga•Jan 7, 2026, 01:02 PM
Protara Therapeutics' TARA-002 Gets FDA's Breakthrough Therapy, Fast Track Designations To Treat Macrocystic, Mixed Cystic Lymphatic Malformations
📈 PositiveBenzinga•Jan 5, 2026, 01:15 PM
Protara Therapeutics shares are trading lower after the company announced the pricing of a $75 million public offering of 13,043,479 shares at $5.75 per share.
📉 NegativeBenzinga•Dec 5, 2025, 02:10 PM
Reported Earlier, Protara Prices $75M Underwritten Public Offering Of 13,043,479 Common Stock Shares At $5.75 Per Share
➖ NeutralBenzinga•Dec 5, 2025, 07:17 AM
Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share
📉 NegativeSeeking Alpha•Dec 5, 2025, 06:01 AM
Protara announces proposed public offering
➖ NeutralSeeking Alpha•Dec 4, 2025, 09:31 PM
Protara Therapeutics shares are trading lower after the company announced a $75 million public offering.
📉 NegativeBenzinga•Dec 4, 2025, 09:30 PM
Protara Therapeutics Announces Proposed $75M Public Offering To Fund Clinical Development Of TARA-002 And Pipeline Programs
➖ NeutralBenzinga•Dec 4, 2025, 09:18 PM
HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target
📈 PositiveBenzinga•Dec 3, 2025, 06:55 PM
Protara Therapeutics Data From Phase 2 ADVANCED-Study Of TARA-002 In Participants With Carcinoma Shows 72% Complete Response Rate; Favorable Safety And Tolerability Profile Observed
📈 PositiveBenzinga•Dec 3, 2025, 01:02 PM
Protara Therapeutics To Review Data From Interim Analysis On Phase 2 ADVANCED-2 Study Of TARA-002 In BCG-Naive Participants With Non-Muscle Invasive Bladder Cancer On Dec. 3
➖ NeutralBenzinga•Dec 1, 2025, 09:18 PM
HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target
📈 PositiveBenzinga•Nov 19, 2025, 04:37 PM•Also:
Protara Therapeutics Announces It Achieves Clinical Success With One Or Two Doses Of TARA-002 In Phase 2 STARBORN-1 Study In 88% Of Participants' No Serious Adverse Events Seen
📈 PositiveBenzinga•Nov 19, 2025, 01:06 PM
Protara Therapeutics To Review New Data From Interim Analysis Of Ongoing Phase 2 Open-Label STARBORN-1 Trial Assessing TARA-002 In Pediatric Patients With LMs, On November 19 Conference Call
➖ NeutralBenzinga•Nov 18, 2025, 09:33 PM
Protara Therapeutics To Present Interim Data From Group A Of Phase 2 ADVANCED-2 Study Of TARA-002 In BCG-Naive Participants With Non-Muscle Invasive Bladder Cancer
📈 PositiveBenzinga•Nov 17, 2025, 01:07 PM
Protara Therapeutics Q3 EPS $(0.31) Beats $(0.38) Estimate
📈 PositiveBenzinga•Nov 10, 2025, 01:14 PM
Frequently Asked Questions about TARA
What is TARA's current stock price?
Protara Therapeutics, Inc. (TARA) is currently trading at $4.96 per share. The stock has moved -5.25% today.
What is the analyst price target for TARA?
The average analyst price target for TARA is $12.00, based on 1 analyst.
What sector is Protara Therapeutics, Inc. in?
Protara Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TARA's market cap?
Protara Therapeutics, Inc. has a market capitalization of $0.19 billion, making it a small-cap company.
Does TARA pay dividends?
No, Protara Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCDXS
Codexis, Inc.
$1.68
Mkt Cap: $0.1B
GNFT
Genfit S.A.
$6.20
Mkt Cap: $0.3B
IVVD
Invivyd, Inc.
$2.27
Mkt Cap: $0.3B
MDWD
MediWound Ltd.
$16.48
Mkt Cap: $0.2B
NTHI
Neonc Technologies Holdings, Inc.
$9.68
Mkt Cap: $0.2B
OABI
OmniAb, Inc.
$1.91
Mkt Cap: $0.2B
OBIO
Orchestra BioMed Holdings, Inc.
$4.33
Mkt Cap: $0.2B
PRLD
Prelude Therapeutics Incorporated
$2.22
Mkt Cap: $0.2B
SGMO
Sangamo Therapeutics, Inc.
$0.44
Mkt Cap: $0.1B
SLS
SELLAS Life Sciences Group, Inc.
$4.04
Mkt Cap: $0.4B
Explore stocks similar to TARA for comparison